Cargando…
An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(® )hydromorphone in patients with chronic cancer pain
BACKGROUND: Opioid analgesics have proven efficacy in the short-term management of chronic cancer pain, but data on their long-term use is more limited. OROS(® )hydromorphone is a controlled-release formulation of oral hydromorphone that may be particularly well suited to long-term management of chr...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753576/ https://www.ncbi.nlm.nih.gov/pubmed/19754935 http://dx.doi.org/10.1186/1472-684X-8-14 |